HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.

Harvard Apparatus Regenerative Technology Inc.

Equities

HRGN

US09074M2026

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 01:39:40 2024-04-25 pm EDT			5-day change	1st Jan Change
2.39 ^USD	+3.02%		+3.02%	-52.10%

Apr. 15	Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	CI
Mar. 28	Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 04:01 pm EDT

Biostage, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.89 million compared to USD 2.18 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.2 a year ago.

Latest news about Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	Apr. 14	CI
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	23-07-18	CI
Transcript : Biostage, Inc. - Special Call	23-06-20
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	23-05-31	CI
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	23-05-31	CI
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Biostage, Inc. announced that it has received $6.005802 million in funding	23-04-12	CI
Biostage, Inc. Appoints Ron Packard to Board of Directors	23-04-10	CI
Biostage, Inc. announced that it expects to receive $6.005802 million in funding	23-03-30	CI
Biostage, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Biostage, Inc Announces Board Changes	23-03-01	CI
Biostage, Inc Announces Executive Changes	23-03-01	CI
Biostage, Inc. Amends CEO Employment Agreement	23-01-12	CI
Biostage, Inc. Announces New Publication Demonstrates Rapid Esophageal Regeneration Using the Biostage Esophageal Implant	22-12-23	CI
Insider Sell: Biostage	22-12-09	MT
Transcript : Biostage, Inc., Q3 2022 Earnings Call, Nov 15, 2022	22-11-15
Biostage, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Biostage, Inc. Announces Appointment of Joseph Damasio as New Chief Financial Officer	22-08-08	CI
Transcript : Biostage, Inc., Q2 2022 Earnings Call, Aug 05, 2022	22-08-05
Biostage, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI

Chart Harvard Apparatus Regenerative Technology Inc.

Duration

Period

Chart Harvard Apparatus Regenerative Technology Inc.

More charts

Company Profile

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patientâs own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.	-52.10%	34.21M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology